Wire · opportunities
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
◆ Sectors
Drug Discovery
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
The US FDA has approved daraxonrasib for the treatment of metastatic pancreatic ductal adenocarcinoma based on positive results from the phase 3 RASolute 302 trial.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 20 sources have reported it.
◆ ◆ The Wire takeaway
This FDA approval opens a new market for pancreatic cancer treatments. You working on oncology drug discovery must move fast to explore combination therapies with daraxonrasib or face losing early adopter oncology centres.
◆ Coverage
20 sources · 26 Aug 2026
◆ Topics
Drug Discoveryfda-approvalpancreatic-cancerdaraxonrasiboncologyphase-3-trial